Levemir-Body Composition and Energy Metabolism

Inclusion Criteria: * Type 2 diabetic patients who require basal (long-acting) insulin for the control of hyperglycemia according to the opinion of the investigator. * Inadequate Glucose control: Hemoglobin A1c (HbA1c) percentage in the range of ≥ 7.5 - 12.0% * Stable body weight for previous 3 months (± 5 kg). * Structured exercise lower than 4 hours per week. * Metformin ≥1.5 g/day Exclusion Criteria: * Any medical, social or geographic condition, which, in the opinion of the investigator would not allow safe or reliable completion of the protocol. * Type 1 Diabetes Mellitus * Previous treatment with insulin (\< 6 months prior inclusion). Insulin therapy for less than 6 days at the time of an acute event is acceptable. * Secondary diabetes mellitus (i.e. steroid induced, Cushing syndrome, chronic pancreatitis, cystic fibrosis, etc.) and maturity-onset diabetes of the young * Proliferative retinopathy/maculopathy requiring treatment * Hypoglycemia unawareness or recurrent major hypoglycaemia * Pregnancy and breast-feeding * Unstable coronary artery disease * Heart Failure as defined by class IV according to NYHA classification * Recent (\< 6 months) history of myocardial infarction, stroke or T.I.A, ventricular arrhythmias, or unstable supra-ventricular arrhythmias. * Renal Insufficiency. Creatinine clearance \< 40 ml/min (MDRD formula). * Acute (\< 2 months) or Chronic infectious diseases requiring either hospitalization or antibiotic treatment for more than 2 weeks * Recent (\< 1 year) diagnosis of systemic malignancies except thyroid and skin cancer * Major psychiatric diseases * History of drug addiction * Previous bariatric surgery * Medication that affects weight such as * Systemic corticosteroids (prednisone) * Anti-obesity medication (Xenical® or Meridia®) * Megace ® * Antidepressant medication associated with significant weight impact such as Zyprexa®, Remeron® based on investigator judgment. * Growth hormone therapy or testosterone supplementation should be initiated for at least 6 months and at stable dose for 3 months prior to enrolment * Medication that affects glycemic control and hypoglycemic unawareness based on investigator judgment.